PD-L1 immune checkpoint molecule is an attractive target for the immunotherapeutic strategies against a range of human malignancies, with a special emphasis on solid tumors.2 16 This is due to the fact that not only PD-L1 molecule, expressed on a significant number of cancer cells, but also other cells within the TME, are documented to inhibit the antitumor function of immune effector cells. Here, CD274 is linked to cancer.